Related Experiment Videos

Cyclosporine induced myocardial fibrosis: a unique controlled case report

The Journal of Heart Transplantation
|February 1, 1985
PubMed

Insights

Cyclosporine can cause perimyocytic fibrosis in transplanted hearts, even without rejection. This drug-induced fibrosis was not observed in the patient's native heart, suggesting it affects only the transplanted organ.

Area of Science:

  • Cardiology
  • Immunosuppression Research
  • Transplantation Medicine

Background:

  • Cyclosporine is a common immunosuppressant used in organ transplantation.
  • Perimyocytic fibrosis has been observed in donor hearts of patients treated with cyclosporine.
  • The effect of cyclosporine on non-transplanted hearts is not well understood.

Observation:

  • A patient with a heterotopic heart transplant was monitored via serial endomyocardial biopsies of both native and donor hearts.
  • The donor heart showed significant perimyocytic fibrosis.
  • The native heart did not exhibit any signs of fibrosis.

Findings:

  • Cyclosporine-induced perimyocytic fibrosis appears to be specific to the transplanted heart.
  • Fibrosis occurred in the absence of any rejection episodes.
  • No restrictive hemodynamic effects were noted up to three years post-transplant.

Implications:

  • Cyclosporine's fibrotic effects may be limited to allografted organs.
  • Further research is needed to understand the mechanisms of cyclosporine-induced fibrosis in transplanted hearts.
  • This finding is relevant for the use of cyclosporine in both cardiac and non-cardiac organ transplantation.

Related Concept Videos